Merck shares fall 9% despite earnings beat, strong demand for top drugs like Keytruda
The drugmaker raised its full-year sales forecast to $63.4 billion to $64.4 billion on increased demand for key products, particularly oncology treatments.
—————
Boost Internet Speed–
Free Business Hosting–
Free Email Account–
Dropcatch–
Free Secure Email–
Secure Email–
Cheap VOIP Calls–
Free Hosting–
Boost Inflight Wifi–
Premium Domains–
Free Domains
